|
|
Article: TOPOTARGET UNVEILS AVUGANE PHASE II TRIAL FOR ACNE VULGARIS.(Clinical report)
- Article from:
- Worldwide Biotech
- Article date:
- June 1, 2007
CopyrightCOPYRIGHT 2007 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TopoTarget A/S (CSE: TOPO), Copenhagen, Denmark, has announced that a Phase II clinical trial has been initiated, testing Avugane, a topical valproic acid - an HDAC inhibitor drug - in the treatment of acne vulgaris. This double-blind, randomised Phase II study comprises four trial arms, testing three different dose strengths of Avugane compared to a placebo control group. The trial follows the positive results with Avugane as previously announced.
This new Phase II study will investigate the efficacy and safety in a four-armed trial with three different dose strengths of topically applied Avugane in the treatment of mild to moderate acne vulgaris in comparison ...